Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt(Bayer (Germany)), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Gerasimos Filippatos(National and Kapodistrian University of Athens), Lars Køber(University of Copenhagen), Peter Kolkhof(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), So Young Kim(Incheon National University), Henry Krum(Australian Regenerative Medicine Institute), Christina Nowack(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Mihai Gheorghiade(Northwestern University), Piotr Ponikowski(Wroclaw Medical University)
Cited by 573
Related Papers
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
|European Journal of Heart Failure|2016|5.9k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k